TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 antimicrobial resistance report identifies 19 pathogens at threat levels ranging from concerning to urgent, plus six on a watch list. Together, the listed pathogens are estimated to cause 9.7 million infections and 50,800 deaths annually in the United States; the report also moves C. difficile from urgent to serious threat status.
The CDC’s updated 2026 antimicrobial resistance report identifies 19 pathogens as concerning, serious or urgent threats and estimates that the listed pathogens collectively cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are classified as urgent threats, while six others appear on a watch list.
The four pathogens at the top tier are Candida auris (also called Candidozyma auris), carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC describes the report as an assessment of infectious agents that threaten public health and require action against antimicrobial resistance.
The report also records changes in classification. Clostridioides difficile moved from urgent to serious threat status; the report attributes the shift in part to infection-prevention measures and falling case numbers since 2011. Drug-resistant N. meningitidis was added to the serious category. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria are among additions to the watch list, which covers potential threats whose disease burden remains uncertain.
Several figures in the report refer to 2023 U.S. data, rather than the annual combined estimate. Reported C. auris cases rose from 48 in 2016 to 4,523 in 2023. Carbapenem-resistant Acinetobacter was associated with 9,497 hospitalizations and an estimated 817 deaths in 2023; carbapenem-resistant Enterobacterales with 14,878 hospitalizations and an estimated 1,252 deaths. Drug-resistant gonorrhea caused an estimated 787,000 infections that year. The report says 55.4% of gonorrhea cases were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations.
Risks for Patients and Care
Antimicrobial resistance can make infections harder to treat when medicines that once worked are less effective. The report’s figures describe a substantial public-health burden, while the individual risks vary by pathogen, patient and setting. Hospital and nursing-home patients can face particular exposure to carbapenem-resistant Acinetobacter, which may spread through contaminated surfaces or equipment. People with ventilators, catheters or extended antibiotic courses are at greater risk from carbapenem-resistant Enterobacterales, according to the source report.
Resistance also has implications beyond the infection itself. Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and raise health-care costs. She warned they can make it harder for doctors to safely provide treatments and procedures such as chemotherapy, organ transplants and joint replacements. That is an attributed assessment of the broader clinical consequences, not a claim that every resistant infection prevents such care.
For gonorrhea, resistance can narrow treatment choices for a common sexually transmitted infection. The source report notes risks including pelvic inflammatory disease, ectopic pregnancy and infertility, as well as increased risk of acquiring or transmitting HIV. The CDC’s categories help signal which pathogens warrant attention, but they do not by themselves describe the risk to any one person.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
As an affiliate, we earn on qualifying purchases.
How the Threat List Changed
The CDC’s report ranks pathogens across urgent, serious and concerning threat levels and separately identifies organisms on a watch list. The categories reflect the agency’s assessment of public-health threats; a watch-list placement signals potential concern where the disease burden is not yet established, rather than a finding that the organism already causes a known level of harm.
The reclassification of C. difficile is a notable change because the report connects its lower category to prevention efforts and declining cases since 2011. The four urgent pathogens include organisms with very different transmission routes and patient impacts: C. auris is a multidrug-resistant yeast that can cause severe infections, especially in people already seriously ill; the other urgent entries include resistant bacteria and the sexually transmitted bacterium that causes gonorrhea.
The source report also notes two FDA approvals from the prior year: gepotidacin (Blujepa) and zoliflodacin (Nuzolvence), described as the first new antibiotics for gonorrhea in decades. Their approval adds treatment options, but it does not establish how widely they will be used or how resistance patterns may change.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Report’s Estimates
The 50,800 deaths and 9.7 million infections are estimates for the pathogens covered collectively; the source material does not break down that combined annual total by pathogen or provide the calculation method. The report’s pathogen-specific hospitalization, death and infection figures cited here are for 2023, and should not be read as current-year counts.
The disease burden of some watch-list organisms remains uncertain, according to the report. The supplied material does not specify all 19 pathogens or provide detailed methods, uncertainty ranges, or the full set of category definitions. It also does not quantify how much prevention measures contributed to the decline in C. difficile cases. Those details would be needed to compare particular pathogens or judge changes in risk more precisely.
Policy and Surveillance Ahead
Armstrong called for passage of the PASTEUR Act, which she said would establish a federal program to support development of antimicrobial drugs for the most threatening pathogens and infections. The source report says versions of the legislation remain stalled in congressional committees; it does not identify a scheduled vote or a timeline for action.
For now, the CDC report provides an updated threat assessment, with surveillance and infection-prevention measures remaining relevant to the pathogens it identifies. The next developments to watch are any movement on the legislation, further CDC reporting on infection and resistance trends, and evidence about the use and effectiveness of newer gonorrhea treatments. The available source does not specify when the CDC will issue its next update.
Key Questions
What does the CDC estimate about these pathogens?
The CDC’s 2026 report estimates that the pathogens it lists collectively cause 9.7 million infections and 50,800 deaths annually in the United States. The supplied material does not give a pathogen-by-pathogen breakdown of that combined estimate.
Which pathogens are classified as urgent threats?
The four urgent threats named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The report reclassified C. difficile from urgent to serious and links the change in part to successful infection-prevention measures and declining case numbers since 2011. The source material does not quantify the contribution of those measures.
What is on the CDC watch list?
Six pathogens are on the watch list of potential threats. The supplied report highlights drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria among its additions; it does not name all six in the provided material.
What happens next with the PASTEUR Act?
The source report says versions of the PASTEUR Act remain stalled in congressional committees. It gives no scheduled vote or timetable. The bill is described as a proposal for a federal program supporting development of antimicrobial drugs for high-priority threats.
Source: medpagetoday.com
